Innovex to manage sales, marketing of Advancis' Keflex Capsules, 333 mg and 750 mg

By Lisa Kerner

Charlotte, N.C., June 22 - Advancis Pharmaceutical Corp. said a two-year agreement with Innovex has Innovex providing contract sales, marketing and commercialization services, including sales representative recruitment, in support of Advancis' 333 mg and 750 mg strengths of its cephalosporin antibiotic, Keflex Capsules (Cephalexin, USP).

Keflex, an oral cephalosporin antibiotic, is shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections, according to a company news release.

Promotion of the capsules to health care professionals is expected to begin on July 17.

Innovex, a unit of Quintiles Transnational Corp., provide sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products.

Advancis, based in Germantown, Md., is focused on the development and commercialization of anti-infective drug products for the treatment of infectious disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.